Cartalax
Cartalax is an oral peptide bioregulator, discussed under the short sequence AED (alanyl-glutamyl-aspartic acid), that is referenced for connective tissue and cartilage support. It has been studied in cell cultures, and its mechanism is proposed, not clinically established.
At a glance
- Bioregulator
- oral
- Not yet audited here; the reference library calls it theoretical
- None on file.
How much to draw
Full calculator →The reference does not report a single injectable amount for Cartalax, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
We have not published an audit on Cartalax. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Cartalax is thought to act by changing how cartilage cells behave and which genes they switch on, though this is a proposal and not a proven drug-receptor model. In one 2023 study, the short peptide AED increased the number of cartilage cells (chondrocytes) in cultures from young and old rats. Researchers link the idea to gene expression, protein synthesis and upkeep of the extracellular matrix, the scaffold around cells. These are cell-culture findings and do not show that Cartalax rebuilds human cartilage or reduces pain.
Tissue-specific peptide bioregulation (theoretical).
Reported side effects
Not ruled out: no Cartalax-specific side-effect data has been published and there is no FDA-approved label, and the source notes that a lack of reports is not proof of safety. It lists immune reactions, impurities, contamination, inconsistent potency and unknown risks as general concerns for unapproved or poorly characterized peptides. These are general concerns, not rates measured for Cartalax.
Who should avoid it
People who are pregnant or breastfeeding: safety is not established for unapproved peptides.
People with active cancer: safety is not established.
People with autoimmune disease or who are immunosuppressed: safety is not established.
People with significant kidney or liver disease: safety is not established.
People with planned surgery or chronic infection: safety is not established.
People on complex medication regimens: drug-interaction data are incomplete, because the clinical studies and safety monitoring that normally map interactions do not exist for Cartalax.
Sources
- pubchem.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- link.springer.com
- mdpi.com
- pmc.ncbi.nlm.nih.gov
- pmc.ncbi.nlm.nih.gov
- pmc.ncbi.nlm.nih.gov
- pmc.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- clinicaltrials.gov
- pmc.ncbi.nlm.nih.gov
- pmc.ncbi.nlm.nih.gov
- doi.org
- doi.org
- pubmed.ncbi.nlm.nih.gov
- doi.org
- doi.org
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.